Literature DB >> 28369380

Late-life depression and the association with multimorbidity and polypharmacy: a cross-sectional study.

Floor Holvast1, Bernard A van Hattem1, Judith Sinnige2,3, François Schellevis3,4, Katja Taxis5, Huibert Burger1, Peter F M Verhaak1,3.   

Abstract

Background: Late-life depression often coincides with chronic somatic diseases and, consequently, with polypharmacy, which may complicate medical treatment. Objective: To determine the associations between patients diagnosed with late-life depression in primary care and multimorbidity and polypharmacy.
Methods: This cross-sectional observational study was performed using 2012 primary care data. Depressed patients aged ≥60 years were compared to age and gender matched patients diagnosed with other psychological diagnoses and mentally healthy controls. Morbidity and prescription data were combined, and regression analyses were performed for the associations between depression and chronic disease and chronic drug use.
Results: We included 4477 patients; 1512 had a record of depression, 1457 of other mental health or psychological diagnoses and 1508 were controls. Depressed patients had a 16% [Prevalence Ratio (PR) 1.16; 95% confidence interval (95% CI) 10%-24%] higher rate of chronic somatic disease and higher odds for multimorbidity (OR 1.55; 95% CI 1.33-1.81) compared with controls. No differences existed between depressed patients and patients with other psychological diagnoses. Compared with controls, depressed patients had a 46% (95% CI 39-53%) higher rate of chronic drug use and higher odds for polypharmacy (OR 2.89; 95% CI 2.41-3.47). Depressed patients also had higher rates of chronic drug use and higher odds for polypharmacy compared with patients with other psychological diagnoses (PR 1.26; OR 1.75; both P < 0.001). Conclusions: Late-life depression in primary care patients is associated with more chronic drug use, even beyond the increased rates of comorbid somatic diseases. General practitioners should consider medication reviews to prevent unnecessary drug-related problems in these patients.
© The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  aged; comorbidity; depression; general practice; polypharmacy; primary health care

Mesh:

Year:  2017        PMID: 28369380     DOI: 10.1093/fampra/cmx018

Source DB:  PubMed          Journal:  Fam Pract        ISSN: 0263-2136            Impact factor:   2.267


  19 in total

1.  Patterns of Association between Depressive Symptoms and Chronic Medical Morbidities in Older Adults.

Authors:  Bruno Agustini; Mojtaba Lotfaliany; Robyn L Woods; John J McNeil; Mark R Nelson; Raj C Shah; Anne M Murray; Michael E Ernst; Christopher M Reid; Andrew Tonkin; Jessica E Lockery; Lana J Williams; Michael Berk; Mohammadreza Mohebbi
Journal:  J Am Geriatr Soc       Date:  2020-05-13       Impact factor: 5.562

2.  Socioeconomic and health factors related to polypharmacy and medication management: analysis of a Household Health Survey in North West Coast England.

Authors:  Jennifer Downing; Rebecca Taylor; Rachael Mountain; Ben Barr; Konstantinos Daras; Terence Comerford; Anthony Guy Marson; Munir Pirmohamed; Frank Dondelinger; Ana Alfirevic
Journal:  BMJ Open       Date:  2022-05-24       Impact factor: 3.006

3.  Late-onset depression is associated to age-related central auditory processing disorder in an older population in Southern Italy.

Authors:  Madia Lozupone; Rodolfo Sardone; Rossella Donghia; Francesca D'Urso; Carla Piccininni; Petronilla Battista; Ilaria Di Gioia; Emanuela Resta; Fabio Castellana; Luisa Lampignano; Roberta Zupo; Ilaria Bortone; Vito Guerra; Chiara Griseta; Davide Seripa; Vincenzo Solfrizzi; Gianluigi Giannelli; Nicola Quaranta; Giancarlo Logroscino; Antonello Bellomo; Francesco Panza
Journal:  Geroscience       Date:  2020-10-31       Impact factor: 7.713

Review 4.  Non-pharmacological treatment for depressed older patients in primary care: A systematic review and meta-analysis.

Authors:  Floor Holvast; Btissame Massoudi; Richard C Oude Voshaar; Peter F M Verhaak
Journal:  PLoS One       Date:  2017-09-22       Impact factor: 3.240

5.  Feasibility, acceptability and potential effectiveness of an information technology-based, pharmacist-led intervention to prevent an increase in anticholinergic and sedative load among older community-dwelling individuals.

Authors:  Helene G van der Meer; Hans Wouters; Martina Teichert; Fabiënne Griens; Jugoslav Pavlovic; Lisa G Pont; Katja Taxis
Journal:  Ther Adv Drug Saf       Date:  2018-10-30

6.  Anticholinergic and sedative medication use in older community-dwelling people: A national population study in the Netherlands.

Authors:  Helene G van der Meer; Katja Taxis; Martina Teichert; Fabiënne Griens; Lisa G Pont; Hans Wouters
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-02-12       Impact factor: 2.890

7.  Physical multimorbidity and subjective cognitive complaints among adults in the United Kingdom: a cross-sectional community-based study.

Authors:  Louis Jacob; Josep Maria Haro; Ai Koyanagi
Journal:  Sci Rep       Date:  2019-08-27       Impact factor: 4.379

8.  The comorbidity conditions and polypharmacy in elderly patients with mental illness in a middle income country: a cross-sectional study⋆.

Authors:  Juliana Dias de Lima; Ivan Abdalla Teixeira; Felipe de Oliveira Silva; Andrea Camaz Deslandes
Journal:  IBRO Rep       Date:  2020-07-16

9.  A surrogate measure for patient reported symptom remission in administrative data.

Authors:  Farrokh Alemi; Mai Aljuaid; Naren Durbha; Melanie Yousefi; Hua Min; Louisa G Sylvia; Andrew A Nierenberg
Journal:  BMC Psychiatry       Date:  2021-03-04       Impact factor: 3.630

10.  Reducing the anticholinergic and sedative load in older patients on polypharmacy by pharmacist-led medication review: a randomised controlled trial.

Authors:  Helene G van der Meer; Hans Wouters; Lisa G Pont; Katja Taxis
Journal:  BMJ Open       Date:  2018-07-19       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.